topotecan has been researched along with carbocyanines in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambudkar, SV; Baer, MR; Bhullar, J; Cai, L; Chen, ZS; Fang, HB; Natarajan, K; Sen, R; Shukla, S | 1 |
1 other study(ies) available for topotecan and carbocyanines
| Article | Year |
|---|---|
The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carbocyanines; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Chlorophyll; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; fms-Like Tyrosine Kinase 3; Fusion Proteins, bcr-abl; Humans; Imidazoles; Inhibitory Concentration 50; Mitoxantrone; Neoplasm Proteins; Protein Binding; Pyridazines; Rhodamine 123; Topotecan | 2012 |